For Pfizer, Bigger as One May Be Better Than Smaller With TwoBy and
Investors, analysts say pricing climate favors bigger company
Pfizer pipeline promising against troubling generic landscape
For Pfizer Inc., bigger is still better.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
You might like: